CN1474692A - 早泄的治疗 - Google Patents

早泄的治疗 Download PDF

Info

Publication number
CN1474692A
CN1474692A CNA018189806A CN01818980A CN1474692A CN 1474692 A CN1474692 A CN 1474692A CN A018189806 A CNA018189806 A CN A018189806A CN 01818980 A CN01818980 A CN 01818980A CN 1474692 A CN1474692 A CN 1474692A
Authority
CN
China
Prior art keywords
pde5
purposes
ethyl
pyrimidin
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018189806A
Other languages
English (en)
Chinese (zh)
Inventor
·
米特拉德夫·布利尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1474692A publication Critical patent/CN1474692A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA018189806A 2000-11-20 2001-11-19 早泄的治疗 Pending CN1474692A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028245.9 2000-11-20
GBGB0028245.9A GB0028245D0 (en) 2000-11-20 2000-11-20 New therapeutic use

Publications (1)

Publication Number Publication Date
CN1474692A true CN1474692A (zh) 2004-02-11

Family

ID=9903491

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018189806A Pending CN1474692A (zh) 2000-11-20 2001-11-19 早泄的治疗

Country Status (21)

Country Link
EP (1) EP1335730B1 (https=)
JP (1) JP2004520279A (https=)
KR (1) KR100595807B1 (https=)
CN (1) CN1474692A (https=)
AT (1) ATE296631T1 (https=)
AU (2) AU2002215149B2 (https=)
BR (1) BR0115413A (https=)
CA (1) CA2429114C (https=)
DE (1) DE60111254T2 (https=)
ES (1) ES2240537T3 (https=)
GB (1) GB0028245D0 (https=)
HU (1) HUP0301915A3 (https=)
IL (1) IL155521A0 (https=)
MX (1) MXPA03003586A (https=)
MY (1) MY131573A (https=)
NZ (1) NZ525167A (https=)
PL (1) PL362058A1 (https=)
PT (1) PT1335730E (https=)
TW (1) TWI280132B (https=)
WO (1) WO2002040027A1 (https=)
ZA (1) ZA200302947B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297869A (zh) * 2020-04-23 2020-06-19 白文智 一种用于治疗早泄和勃起功能障碍的复方制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297869A (zh) * 2020-04-23 2020-06-19 白文智 一种用于治疗早泄和勃起功能障碍的复方制剂

Also Published As

Publication number Publication date
DE60111254D1 (de) 2005-07-07
AU1514902A (en) 2002-05-27
EP1335730B1 (en) 2005-06-01
GB0028245D0 (en) 2001-01-03
ATE296631T1 (de) 2005-06-15
IL155521A0 (en) 2003-11-23
NZ525167A (en) 2005-02-25
BR0115413A (pt) 2003-10-07
JP2004520279A (ja) 2004-07-08
WO2002040027A1 (en) 2002-05-23
KR100595807B1 (ko) 2006-07-03
MXPA03003586A (es) 2003-07-14
PT1335730E (pt) 2005-09-30
PL362058A1 (en) 2004-10-18
CA2429114C (en) 2007-09-11
DE60111254T2 (de) 2006-05-04
HUP0301915A3 (en) 2007-03-28
TWI280132B (en) 2007-05-01
HUP0301915A2 (hu) 2003-09-29
CA2429114A1 (en) 2002-05-23
KR20030048476A (ko) 2003-06-19
EP1335730A1 (en) 2003-08-20
ES2240537T3 (es) 2005-10-16
AU2002215149B2 (en) 2006-04-06
ZA200302947B (en) 2004-04-28
MY131573A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
US20080153841A1 (en) Treatment of premature ejaculation
US20020165237A1 (en) Treatment of the insulin resistance syndrome
CN1446084A (zh) 胰岛素抗性综合症的治疗
JP2007516949A (ja) 性機能不全の治療
JP2005519927A (ja) 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用
TW200407153A (en) Novel combination
CN1474692A (zh) 早泄的治疗
JP2008150371A (ja) 性機能障害を治療するための化合物
CN1662257A (zh) Pde5抑制剂与血管紧张肽ⅱ受体拮抗剂的联用药物
AU2002215149A1 (en) Treatment of premature ejaculation
JP2009520806A (ja) ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ
HK1059043A (en) Treatment of premature ejaculation
JP4533590B2 (ja) 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
US20050054688A1 (en) Selective serotonin reuptake inhibitors in the treatment of disease
JP2006528171A (ja) 男性機能障害の治療
US20050026810A1 (en) Treatment of male sexual dysfunction
HK1055900A (en) Treatment of the insulin resistance syndrome
HK1077219A (en) Combination of pde5 inhibitors with angiotensin ii receptor antagonists
HK1076380A (en) Pharmaceutical combination of pde5 inhibitors with ace inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059043

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1059043

Country of ref document: HK